S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NASDAQ:PLSEPulse Biosciences Stock Price, Forecast & News

$11.06
+0.81 (+7.90 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.35
Now: $11.06
$11.24
50-Day Range
$8.05
MA: $10.35
$11.84
52-Week Range
$5.11
Now: $11.06
$17.45
Volume62,011 shs
Average Volume114,982 shs
Market Capitalization$230.81 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03
Pulse Biosciences, Inc. operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.
Read More
Pulse Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.17 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PLSE
CUSIPN/A
Phone510-906-4600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.48 per share

Profitability

Net Income$-46,970,000.00

Miscellaneous

Employees54
Market Cap$230.81 million
Next Earnings Date8/10/2020 (Confirmed)
OptionableOptionable
$11.06
+0.81 (+7.90 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PLSE News and Ratings via Email

Sign-up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pulse Biosciences (NASDAQ:PLSE) Frequently Asked Questions

How has Pulse Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Pulse Biosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PLSE stock has increased by 73.9% and is now trading at $11.06.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Pulse Biosciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pulse Biosciences
.

When is Pulse Biosciences' next earnings date?

Pulse Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Pulse Biosciences
.

How can I listen to Pulse Biosciences' earnings call?

Pulse Biosciences will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences Inc (NASDAQ:PLSE) announced its earnings results on Monday, May, 11th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.10.
View Pulse Biosciences' earnings history
.

What price target have analysts set for PLSE?

1 brokers have issued 1-year price targets for Pulse Biosciences' stock. Their forecasts range from $16.00 to $16.00. On average, they anticipate Pulse Biosciences' stock price to reach $16.00 in the next year. This suggests a possible upside of 44.7% from the stock's current price.
View analysts' price targets for Pulse Biosciences
.

Has Pulse Biosciences been receiving favorable news coverage?

Media stories about PLSE stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pulse Biosciences earned a daily sentiment score of 1.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Pulse Biosciences
.

Are investors shorting Pulse Biosciences?

Pulse Biosciences saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,770,000 shares, an increase of 9.1% from the June 15th total of 2,540,000 shares. Based on an average daily trading volume, of 141,800 shares, the days-to-cover ratio is presently 19.5 days. Currently, 26.8% of the shares of the stock are sold short.
View Pulse Biosciences' Current Options Chain
.

Who are some of Pulse Biosciences' key competitors?

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), Bausch Health Companies (BHC), Wayfair (W), AbbVie (ABBV), Achaogen (AKAO), Portola Pharmaceuticals (PTLA), Roku (ROKU), Exelixis (EXEL), Fate Therapeutics (FATE) and Ring Energy (REI).

Who are Pulse Biosciences' key executives?

Pulse Biosciences' management team includes the following people:
  • Mr. Darrin R. Uecker, Pres, CEO & Director (Age 53)
  • Mr. Brian B. Dow, CFO, Sr. VP of Fin. & Admin., Treasurer and Sec. (Age 50)
  • Mr. Edward A. Ebbers, Exec. VP & GM of Dermatology (Age 59)
  • Dr. Richard Nuccitelli Ph.D., Chief Science Officer
  • Dr. Holly Hartman Ph.D., J.D., VP of Bus. Devel. & Corp. Strategy

When did Pulse Biosciences IPO?

(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.

What is Pulse Biosciences' stock symbol?

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Westside Investment Management Inc. (0.17%), TIAA FSB (0.13%), Spotlight Asset Group Inc. (0.08%) and UBS Group AG (0.06%).
View institutional ownership trends for Pulse Biosciences
.

Which major investors are selling Pulse Biosciences stock?

PLSE stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Pulse Biosciences
.

Which major investors are buying Pulse Biosciences stock?

PLSE stock was acquired by a variety of institutional investors in the last quarter, including TIAA FSB, Spotlight Asset Group Inc., and Westside Investment Management Inc..
View insider buying and selling activity for Pulse Biosciences
.

How do I buy shares of Pulse Biosciences?

Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pulse Biosciences' stock price today?

One share of PLSE stock can currently be purchased for approximately $11.06.

How big of a company is Pulse Biosciences?

Pulse Biosciences has a market capitalization of $230.81 million. The company earns $-46,970,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Pulse Biosciences employs 54 workers across the globe.

What is Pulse Biosciences' official website?

The official website for Pulse Biosciences is www.pulsebiosciences.com.

How can I contact Pulse Biosciences?

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.